Instrument Inactif

Autres langues Cubist Pharmaceuticals Inc

Actions

US2296781071

Produits pharmaceutiques

Cours en clôture Nasdaq
- ^USD	-

09/12/14	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin	RE
08/12/14	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars	RE

Autres langues

13/01/15	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market
21/12/14	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
20/12/14	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections
10/12/14	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug
09/12/14	Cubist Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Cubist Pharmaceuticals Inc.
09/12/14	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback
09/12/14	Merck : to take on superbugs with Cubist Pharma buy
09/12/14	Cubist Pharmaceuticals : Comments on CUBICIN Patent Litigation
09/12/14	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy
08/12/14	Apple : S&P 500 posts worst day since Oct; energy shares sink
08/12/14	Cubist Pharmaceuticals : options unusually active before Merck deal
08/12/14	CUBIST PHARMACEUTICALS : ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Cubist Pharmaceuticals, Inc. to Merck
06/12/14	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT
17/11/14	Cubist Pharmaceuticals : European Antibiotic Awareness Day Highlights Need for Urgent Action
17/11/14	Cubist Pharmaceuticals : Europäischer Antibiotikatag unterstreicht dringenden Handlungsbedarf
17/11/14	Cubist Pharmaceuticals : Europäischer Antibiotikatag unterstreicht dringenden Handlungsbedarf
05/11/14	Cubist Pharmaceuticals : Names Dr. Patrick Vink Chief Operating Officer
03/11/14	Cubist Pharmaceuticals : to Present at Jefferies 2014 Healthcare Conference
21/10/14	Cubist Pharmaceuticals : Reports Third Quarter 2014 Financial Results
21/10/14	Cubist Pharmaceuticals : Technical Data on Biotech Equities - Intrexon, Keryx Biopharma, Spectrum Pharma, Sangamo BioSciences, and Cubist Pharma
20/10/14	Cubist Pharmaceuticals : Names Robert J. Perez Chief Executive Officer
14/10/14	Cubist Pharmaceuticals : to Announce Third Quarter 2014 Financial Results on Tuesday, October 21, 2014
08/10/14	Cubist Pharmaceuticals : to Present New Data from Study of fidaxomicin in Children with Clostridium Difficile-Associated Diarrhea at IDWeek 2014
30/09/14	Cubist Pharmaceuticals : to Present New Data on Antibiotics Portfolio at IDWeek 2014
18/09/14	Cubist Pharmaceuticals : setzt weltweite Expansion mit Eröffnung seines internationalen Hauptsitzes in Zürich fort